Phenylhydrazone-based endoplasmic reticulum proteostasis regulator compounds with enhanced biological activity
eLife · 2026
DOI: 10.7554/elife.107000 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Gabriel M Kline und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The Scripps Research Institute, San Diego, United States. Hauptthemen laut MEDLINE: Proteostasis, Endoplasmic Reticulum, Hydrazones. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NINDS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Pharmacological enhancement of endoplasmic reticulum (ER) proteostasis is an attractive strategy to mitigate pathology linked to etiologically diverse protein misfolding diseases. However, despite this promise, few compounds have been identified that enhance ER proteostasis through defined mechanisms of action. We previously identified the phenylhydrazone-based compound AA263 as a molecule that promotes adaptive ER proteostasis remodeling through mechanisms including preferential activation of the ATF6 signaling arm of the unfolded protein response (Plate et al., 2016). However, the protein target(s) of AA263 and the potential for further development of this class of ER proteostasis regulators had not been previously explored. Here, we employ chemical proteomics to demonstrate that AA263 covalently targets a subset of ER protein disulfide isomerases, revealing a potential molecular mechanism for the activation of ATF6 afforded by this compound. We then use medicinal chemistry to establish next-generation AA263 analogs showing improved potency and efficacy for ATF6 activation, as compared to the parent compound. Finally, we show that treatment with these AA263 analogs enhances secretory pathway proteostasis to correct the pathologic protein misfolding and trafficking of both a destabilized, disease-associated α1-antitrypsin (A1AT) variant and an epilepsy-associated GABA A receptor variant. These results establish AA263 analogs with enhanced potential for correcting imbalanced ER proteostasis associated with etiologically diverse protein misfolding disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, The Scripps Research Institute, San Diego, United States.
- The Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, United States.
- Department of Molecular and Cellular Biology, The Scripps Research Institute, San Diego, United States.
ORCID-Profile: William E Balch, Jeffery W Kelly, Tingwei Mu, R Luke Wiseman
Förderung
- NIH HHS
- NINDS NIH HHS
- NHLBI NIH HHS
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Kline, G. M., Boinon, L., Guerrero, A., Kutseikin, S., Cruz, G., Williams, M. P., Paxman, R. J., Balch, W. E., Kelly, J. W., Mu, T., & Wiseman, R. L. (2026). Phenylhydrazone-based endoplasmic reticulum proteostasis regulator compounds with enhanced biological activity. eLife. https://doi.org/10.7554/elife.107000
Vancouver
Kline GM, Boinon L, Guerrero A, Kutseikin S, Cruz G, Williams MP, et al. Phenylhydrazone-based endoplasmic reticulum proteostasis regulator compounds with enhanced biological activity. eLife. 2026. doi:10.7554/elife.107000
BibTeX
@article{Kline2026,
author = {Kline, Gabriel M and Boinon, Lisa and Guerrero, Adrian and Kutseikin, Sergei and Cruz, Gabrielle and Williams, Marnie P and Paxman, Ryan J and Balch, William E and Kelly, Jeffery W and Mu, Tingwei and Wiseman, R Luke},
title = {Phenylhydrazone-based endoplasmic reticulum proteostasis regulator compounds with enhanced biological activity},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.107000}
}
EUVIMED